While a direct influence of lapatinib on blood flow was not reported in the literature, an anti-angiogenic effect in lung cancer xenografts and an anti-vascular effect in a rat model for corneal neovascularization has been reported following lapatinib administration, purportedly through downregulation of VEGF [52,53]. This evidence concerns the gene VEGFA and lung cancer.